Table 1 Demographic and clinical characteristics of patients
From: Tumor attachment to Major intrahepatic vascular for Colorectal liver metastases
R0(n = 167) | R1V(n = 58) | R1P(n = 58) | p | |
|---|---|---|---|---|
Age(years) | 56.1 ± 9.5 | 58.1 ± 8.1 | 58.8 ± 9.7 | 0.113 |
Sex(M) | 108(64.7%) | 43(74.1%) | 37(63.8%) | 0.376 |
Primary tumor | ||||
Rectal/Colon | 62/105 | 20/38 | 21/37 | 0.937 |
Right/Left | 27/140 | 8/50 | 11/47 | 0.751 |
T1-2 | 11(6.6%) | 3(5.2%) | 5(8.6%) | 0.755 |
T3-4 | 156(93.4%) | 55(94.8%) | 53(91.4%) | |
Primary Node | ||||
(-) | 40(24.0%) | 22(37.9%) | 17(29.3%) | 0.119 |
( +) | 127(76.0%) | 36(62.1%) | 41(70.7%) | |
Liver metastases | ||||
Synchronous | 151(90.4%) | 51(87.9%) | 54(93.1%) | 0.638 |
Metachronous | 16(9.6%) | 7(12.1%) | 4(6.9%) | |
No. of metastases (median) | 4(1–20) | 4(1–20) | ||
Single metastases | 26(15.6%) | 11(19.0%) | 4(6.9%) | 0.15 |
Multiple metastases | 141(84.4%) | 47(81.0%) | 54(93.1%) | |
Tumor size | ||||
> 50 mm | 25(15.0%) | 15(25.9%) | 8(13.8%) | 0.126 |
≤ 50 mm | 142(85.0%) | 43(74.1%) | 50(86.2%) | |
Unilobar | 49(29.3%) | 16(27.6%) | 6(10.3%) | 0.014 |
Bilobar | 118(70.7%) | 42(72.4%) | 52(89.7%) | |
Extrahepatic disease | 35(21.0%) | 5(8.6%) | 13(22.4%) | 0.084 |
CEA | 26.64 ± 63.50 | 33.04 ± 79.02 | 29.53 ± 70.16 | 0.697 |
CA199 | 100.74 ± 38.68 | 46.27 ± 66.61 | 94.41 ± 52.16 | 0.435 |
CRS(0–2) | ||||
CRS(3–5) | ||||
Preoperative chemotherapy | ||||
Neoadjuvant chemotherapy | 77(46.1%) | 28(48.3%) | 19(32.8%) | 0.15 |
Conversional chemotherapy | 90(53.9%) | 30(51.7%) | 39(67.2%) | |
Oxaliplatin | 60(35.9%) | 15(25.9%) | 26(44.8%) | 0.328 |
R0(n = 167) | R1V(n = 58) | R1P(n = 58) | p | |
Irinotecan | 52(31.1%) | 20(34.5%) | 15(25.9%) | |
Both | 55(33.0%) | 23(39.6%) | 17(29.3%) | |
Ass bevacizumab | 80(47.9%) | 28(48.3%) | 26(44.8%) | 0.367 |
Ass cetuximab | 67(40.1%) | 24(41.4%) | 22(37.9%) | |
Both | 3(1.8%) | 0(0%) | 4(6.9%) | |
None | 17(10.2%) | 6(10.3%) | 6(10.3%) | |
Number of lines > 1 | 40(24.0%) | 21(36.2%) | 16(27.6%) | 0.195 |
Number of cycles | 5(2–23) | 5(2–16) | 5(2–14) | 0.664 |
Response | 0.963 | |||
PR | 100(59.9%) | 33(56.9%) | 37(63.8%) | |
SD | 64(38.3%) | 24(41.4%) | 20(34.5%) | |
PD | 3(1.8%) | 1(1.7%) | 1(1.7%) | |
Adjuvant chemo | 137(82.0%) | 47(81.0%) | 44(75.9%) | 0.530 |
RAS mutation | 80(47.9%) | 17(29.3%) | 25(43.1%) | 0.048 |
Before preoperative chemo | ||||
Tumor attachment of vessels | 219 | 103 | ||
After preoperative chemo | ||||
Anatomic resection | 58(34.7%) | 15(25.9%) | 43(74.1%) | 0.445 |
PSH | 109(65.3%) | 43(74.1%) | 15(25.9%) | |
Blood loss(ml) | 244.0 ± 66.1 | 278.3 ± 20.5 | 306.0 ± 62.6 | 0.098 |
Major complication | ||||
0-II | 160 | 56 | 55 | 0.133 |
III-IV | 7 | 2 | 3 | |
Blood transfusion | 9 | 1 | 6 | 0.129 |